Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: Systematic review and economic evaluation

Health Technology Assessment

Volumn 20, Issue 38, 2016, Pages 1-678

  Auguste, Peter ^a   Tsertsvadze, Alexander ^a   Pink, Joshua ^a   Court, Rachel ^a   Seedat, Farah ^a   Gurung, Tara ^a   Freeman, Karoline ^a   Taylor Phillips, Sian ^a   Walker, Clare ^a   Madan, Jason ^a   Kandala, Ngianga Bakwin ^b   Clarke, Aileen ^a   Sutcliffe, Paul ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b NORTHUMBRIA UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; ECONOMIC EVALUATION; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; QUALITY ADJUSTED LIFE YEAR; SYSTEMATIC REVIEW; TUBERCULIN TEST; UNITED KINGDOM; ADOLESCENT; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MASS SCREENING; NATIONAL HEALTH SERVICE; PRESCHOOL CHILD; PROCEDURES; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARDS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; INFANT; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; MASS SCREENING; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; STATE MEDICINE; TUBERCULIN TEST; UNITED KINGDOM;

EID: 84969920919     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta20380     Document Type: Article

References (231)

1. World Health Organization. Global Tuberculosis Report 2013. Geneva: World Health Organization; 2013.
2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282:677-86. http://dx.doi.org/10.1001/jama.282.7.677
3. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994;72:213-20.
4. Anderson L, Moore J, Kruijshaar M, Pedrazzoli D, Bradshaw L, Crofts J, et al. Tuberculosis in the UK: Report on Tuberculosis Surveillance and Control in the UK 2010. London: Health Protection Agency; 2010.
5. Pedrazzoli D. Tuberculosis in the UK: Annual Report on Tuberculosis Surveillance in the UK, 2013. London: Public Health England; 2013.
6. Pareek M, Watson JP, Ormerod LP, Kon OM, Woltmann G, White PJ, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and costeffectiveness analysis. Lancet Infect Dis 2011;11:435-44. http://dx.doi.org/10.1016/S1473-3099(11)70069-X
7. Public Health England. Collaborative Tuberculosis Strategy for England 2014 to 2019: For Consultation. 2014. URL: www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317140970182 (accessed 1 July 2015).
8. Centers for Disease Control and Prevention. Transmission and Pathogenesis of Tuberculosis. In Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th edn. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
9. Doran P, Carson J, Costello E, More SJ. An outbreak of tuberculosis affecting cattle and people on an Irish dairy farm, following the consumption of raw milk. Ir Vet J 2009;62:390. http://dx.doi.org/10.1186/2046-0481-62-6-390
10. National Collaborating Centre for Chronic Conditions, Centre for Clinical Practice at the National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. CG117. London: NICE; 2011. URL: www.ncbi.nlm.nih.gov/books/NBK97852/ (accessed 27 February 2014).
11. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20. http://dx.doi.org/10.1128/CMR.00034-13
12. Al-Orainey IO. Diagnosis of latent tuberculosis: can we do better? Ann Thorac Med 2009;4:5-9. http://dx.doi.org/10.4103/1817-1737.44778
13. Herrera V, Perry S, Parsonnet J, Banaei N. Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 2011;52:1031-7.http://dx.doi.org/10.1093/cid/cir068
14. World Health Organization. Tuberculosis: Factsheet 104. 2014. URL: www.who.int/mediacentre/factsheets/fs104/en/ (accessed 8 January 2015).
15. Taylor ZNC, Blumberg HM, for the American Thoracic Society; Centers for Disease Control and Prevention; and Infectious Diseases Society of America. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recomm Rep 2005;54:1-81.
16. Hauck FR, Neese BH, Panchal AS, El-Amin W. Identification and management of latent tuberculosis infection. Am Fam Physician 2009;79:879-86.
17. Bakhshi SS, Hawker J, Ali S. The epidemiology of tuberculosis by ethnic group in Birmingham and its implications for future trends in tuberculosis in the UK. Ethn Health 1997;2:147-53. http://dx.doi.org/10.1080/13557858.1997.9961823
18. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45-55. http://dx.doi.org/10.1016/S1473-3099(11)70210-9
19. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-90. http://dx.doi.org/10.1016/j.jclinepi.2005.02.022
20. Centers for Disease Control and Prevention. Diagnosis of Tuberculosis Disease. In Core Curriculum on Tuberculosis: What the Clinician Should Know. 6th edn. Atlanta, GA: Centers for Disease Control and Prevention; 2013.
21. Cunningham J, Perkins M, Mwaluko G, Wringe A, Todd J, Glynn JR, et al. Diagnostics for tuberculosis: global demand and market potential. Lancet 2007;369:612-13.
22. Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins Basic Pathology. 8th edn. Philadelphia, PA: Saunders Elsevier; 2007.
23. US Department of Agriculture, Food Safety and Inspection Service. Tuberculosis: What You Need To Know. Washington, DC: US Department of Agriculture, Food Safety and Inspection Service; 1997.
24. Chaulk C, Kazandjian V. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the Public Health Tuberculosis Guidelines Panel. JAMA 1998;279:943-8. http://dx.doi.org/10.1001/jama.279.12.943
25. Chaulet P. Treatment of Tuberculosis: Case Holding until Cure. WHO/TB/83.141. Geneva: World Health Organization; 1983.
26. GBC Health. Drug-Resistant TB: Why It Matters. 2011. URL: www.gbchealth.org/system/documents/category_1/7/GBCHealth%20Issue%20Brief_Drug-Resistant%20TB.pdf?1311656059 (accessed 8 January 2015).
27. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95. http://dx.doi.org/10.1164/ajrccm.161.4.16141
28. Great Britain. Public Health (Control of Disease) Act 1984. London: The Stationery Office; 1984.
29. Public Health England. UK Tuberculosis (TB) Surveillance Data. 2014. URL: www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Tuberculosis/TBUKSurveillanceData/ (accessed 1 July 2014).
30. Health Protection Agency. Statutory notifications of tuberculosis. Commun Dis Rep CDR Wkly 2004;14.
31. Euro TB. Total TB Cases and TB Notification Rates, 1995-2006, WHO European Region. 2006. URL: www.eurotb.org/slides/2008/TBCases_Rates1995-2006.pdf (accessed 27 February 2014).
32. Health Protection Agency. Migrant Health: Infectious Diseases in Non-UK Born Populations in England, Wales, and Northern Ireland. A Baseline Report - 2006. London: Health Protection Agency Centre for Infections; 2006.
33. McCarthy OR. Asian immigrant tuberculosis - the effect of visiting Asia. Br J Dis Chest 1984;78:248-53. http://dx.doi.org/10.1016/0007-0971(84)90136-0
34. Moore-Gillon J. Diabetes and tuberculosis: a gathering storm? Thorax 2010;65:571-2. http://dx.doi.org/10.1136/thx.2009.134247
35. The Lancet. The ongoing problem of tuberculosis in the UK. Lancet 2013;381:1431. http://dx.doi.org/10.1016/S0140-6736(13)60910-1
36. Kirby T. Tuberculosis rates unacceptably high in UK cities. Lancet Infect Dis 2013;13:836-7. http://dx.doi.org/10.1016/S1473-3099(13)70276-7
37. Rienzo C, Vargas-Silva C. Migrants in the UK Overview. Migration Observatory; 2013. URL: www.migrationobservatory.ox.ac.uk/briefings/migrants-uk-overview (accessed 1 July 2014).
38. Anderson C, Anderson S, Kanagarajah S, Hamblion E. Tuberculosis in London: Annual Review (2011 Data). London: Health Protection Agency, Regional Epidemiology Unit; 2012.
39. Krausova A, Vargas-Silva C. London: Census Profile. Migration Observatory; 2013. URL: www.migrationobservatory.ox.ac.uk/briefings/london-census-profile (accessed 1 July 2014).
40. Cattamanchi A, Smith R, Steingart KR, Metcalfe JZ, Date A, Coleman C, et al. Interferon-gamma release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011;56:230-8. http://dx.doi.org/10.1097/QAI.0b013e31820b07ab
41. Pawlowski A, Jansson M, Sköld M, Rottenberg M, Källenius G. Tuberculosis and HIV co-infection. PLOS Pathog 2012;8: 1002464. http://dx.doi.org/10.1371/journal.ppat.1002464
42. Sharma S, Mohan A, Kadhiravan T. HIV-TB co-infection: epidemiology, diagnosis and management. Indian J Med Res 2005;121:550-67.
43. McShane H. Co-infection with HIV and TB: double trouble. Int J STD AIDS 2005;16:95-101. http://dx.doi.org/10.1258/0956462053057576
44. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007;11(3). http://dx.doi.org/10.3310/hta11030
45. Vyas JM. Pulmonary Tuberculosis. MedlinePlus; 2013. URL: www.nlm.nih.gov/medlineplus/ency/article/000077.htm (accessed 1 July 2015).
46. Marra CA, Marra F, Cox VC, Palepu A, Fitzgerald JM. Factors influencing quality of life in patients with active tuberculosis. Health Qual Life Outcomes 2004;2:58. http://dx.doi.org/10.1186/ 1477-7525-2-58
47. Thorn P. Overcoming Tuberculosis: A Handbook for Patients. Geneva: Stop TB Partnership; 2007. URL: www.stoptb.org/assets/documents/resources/publications/acsm/overcomingTB.pdf (accessed 1 July 2015).
48. Courtwright A, Turner AN. Tuberculosis and stigmatization: pathways and interventions. Public Health Rep 2010;125(4):34-42.
49. Substance Abuse and Mental Health Services Administration. The Facts about Tuberculosis. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 1995.
50. London TB Community. Case for Change: TB Services in London. London: London Health Programmes; 2011.
51. National Collaborating Centre for Chronic Conditions, Centre for Clinical Practice at the National Institute for Health and Care Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. CG33. London: NICE; 2006. URL: www.nice.org.uk/guidance/CG033 (accessed 5 August 2014).
52. National Institute for Health and Care Excellence. Identifying and Managing Tuberculosis among Hard-to-Reach Groups. PH37. London: NICE; 2012. URL: www.nice.org.uk/guidance/ph37 (accessed 1 July 2014).
53. Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006;28:35-44. http://dx.doi.org/10.1183/09031936.06.00011806
54. Chaparas SD, Vandiviere HM, Melvin I, Koch G, Becker C. Tuberculin test. Variability with the Mantoux procedure. Am Rev Respir Dis 1985;132:175-7.
55. Perez-Stable EJ, Slutkin G. A demonstration of lack of variability among six tuberculin skin test readers. Am J Public Health 1985;75:1341-3. http://dx.doi.org/10.2105/AJPH.75.11.1341
56. Andersen P, Munk ME, Pollock JM, Doherty TM. Specific immune-based diagnosis of tuberculosis. Lancet 2000;356:1099-104. http://dx.doi.org/10.1016/S0140-6736(00)02742-2
57. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007;146:340-54. http://dx.doi.org/10.7326/0003-4819-146-5-200703060-00006
58. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011;37:88-99. http://dx.doi.org/10.1183/09031936.00115110
59. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, Hanekom W, et al. The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J 2011;30:694-700. http://dx.doi.org/10.1097/INF.0b013e318214b915
60. Girardi E, Angeletti C, Puro V, Sorrentino R, Magnavita N, Vincenti D, et al. Estimating diagnostic accuracy of tests for latent tuberculosis infection without a gold standard among healthcare workers. Euro Surveill 2009;14:19373.
61. Ahitan M, Smith G. Latent Tuberculosis Treatment with Rifapentine and Isoniazid by Directly Observed Therapy. Birmingham: Heart of England NHS Foundation Trust; 2013. URL: http://tuberculosis.heartofengland.nhs.uk/wp-content/uploads/g2.pdf (accessed 1 July 2014).
62. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011;60:1650-3.
63. Department of Health. Tuberculosis Prevention and Treatment: A Toolkit for Planning, Commissioning and Delivering High-Quality Services in England. London: Department of Health; 2007.
64. Department of Health. Health Clearance for Tuberculosis, Hepatitis B, Hepatitis C and HIV: New Healthcare Workers. London: Department of Health; 2007.
65. Department of Health. Stopping Tuberculosis in England: An Action Plan from the Chief Medical Officer. London: Department of Health; 2004.
66. Department of Health. The Interdepartmental Working Group on Tuberculosis: The Prevention and Control of Tuberculosis in the United Kingdom. London: Department of Health; 1998.
67. British Thoracic Society Standards of Care Committee and Joint Tuberculosis Committee, Milburn H, Ashman N, Davies P, Doffman S, Drobniewski F, Khoo S, et al. Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax 2010;65557-70. http://dx.doi.org/10.1136/thx.2009.133173
68. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5. http://dx.doi.org/10.1136/thx.2005.046797
69. British Thoracic Society Standards of Care Committee. Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. Thorax 2002;57:289-304.
70. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000;55:210-18. http://dx.doi.org/10.1136/thorax.55.3.210
71. London Health Programmes. Model of Care: TB Services in London. London: London Health Programmes, National Health Service; 2011.
72. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011;133:257-66.
73. Trajman A, Steffen RE, Menzies D. Interferon-gamma release assays versus tuberculin skin testing for the diagnosis of latent tuberculosis infection: an overview of the evidence. Pulm Med 2013;2013:601737. http://dx.doi.org/10.1155/2013/601737
74. Public Health England. Latent TB Testing and Treatment for Migrants: A Practical Guide for Commissioners and Practitioners. London: Public Health England; 2015. URL: www.gov.uk/government/uploads/system/uploads/attachment_data/file/442192/030615_LTBI_testing_and_treatment_for_migrants_1.pdf (accessed 3 May 2016).
75. Kawamura LM. IGRAs in public health practice: economic issues. Int J Tuberc Lung Dis 2010;14(1): 60-3.
76. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 2008;12:1352-64.
77. Pareek M, Bond M, Shorey J, Seneviratne S, Guy M, White P, et al. Community-based evaluation of immigrant tuberculosis screening using interferon gamma release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013;68:230-9. http://dx.doi.org/10.1136/thoraxjnl-2011-201542
78. National Institute for Health Research. Prognostic Value of Interferon Gamma Release Assays in Predicting Active Tuberculosis among Individuals with, or at Risk of, Latent Tuberculosis Infection. National Institute for Health Research; 2010. URL: www.nets.nihr.ac.uk/projects/hta/086801 (accessed 15 January 2015).
79. Public Health England. Tuberculosis Screening. 2014. URL: www.gov.uk/guidance/tuberculosis-screening (accessed 10 February 2016).
80. Junghans C, Anya I, Brodie C, Carter S. Tuberculosis (TB): An Epidemiological Analysis and Review of Service Provision in Hammersmith and Fulham, Kensington and Chelsea, and Westminster. Tri-Borough Joint Strategic Needs Assessment Report 2014. 2014. URL: www.jsna.info/sites/default/files/Tuberculosis%20%28TB%29%20JSNA%202014.pdf (accessed 4 August 2014).
81. Theaker S. Tuberculosis Summary Needs Assessment. Leicester, Leicestershire and Rutland. TB Strategy Board, Leicester City Council; 2013. URL: www.leicester.gov.uk/EasySiteWeb/GatewayLink.aspx?alId=222528 (accessed 8 July 2014).
82. Kirklees Joint Strategic Needs Assessment. Infectious Disease and Human Immunodeficiency Virus (HIV). 2014. URL: www.kirklees.gov.uk/you-kmc/partners/health/jsna/pdf/KirkleesJSNAInfectiousdiseaseandHIV.pdf (accessed 4 August 2014).
83. Manchester City Council Joint Strategic Needs Assessment. Tuberculosis (TB). 2014. URL: www.manchester.gov.uk/info/500230/joint_strategic_needs_assessment/6110/tuberculosis_tb (accessed 4 August 2014).
84. Dedicoat M. Birmingham and Solihull Tuberculosis Service: South and City Colleage Birmingham Tackles TB. 2014. URL: http://tuberculosis.heartofengland.nhs.uk/south-city-college-birminghamtackles-tb/ (accessed 4 August 2014).
85. Newcastle upon Tyne Hospitals NHS Foundation Trust. TB Service. www.newcastle-hospitals.org.uk/services/NHCH_services_community-nursing_tb.aspx (accessed 29 February 2016).
86. Birmingham and Solihull TB services. Tuberculosis. URL: www.heartofengland.nhs.uk/tuberculosis/ (accessed 10 February 2016).
87. Liverpool Community Health NHS Trust. Tuberculosis (TB) Service 2014. URL: www.liverpoolcommunityhealth.nhs.uk/health-services/nursing-services/tb-service.htm (accessed 10 February 2016).
88. National Institute for Health and Care Excellence. Diagnostics Assessment Programme Manual. London: NICE; 2011. URL: www.nice.org.uk/media/A0B/97/DAPManualFINAL.pdf (accessed 18 March 2014).
89. National Institute for Health and Care Excellence. Diagnostic Assessments Programme Manual. London: NICE; 2012. URL: www.nice.org.uk/Media/Default/About/what-we-do/NICE-guidance/NICE-diagnostics-guidance/Diagnostics-assessment-programme-manual.pdf (accessed 10 February 2016).
90. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med 2013;158:280-6. http://dx.doi.org/10.7326/0003-4819-158-4-201302190-00009
91. Ling DI, Zwerling AA, Steingart KR, Pai M. Immune-based diagnostics for TB in children: what is the evidence? Paediatr Respir Rev 2011;12:9-15. http://dx.doi.org/10.1016/j.prrv.2010.09.009
92. Reitsma JB, Rutjes AW, Khan KS, Coomarasamy A, Bossuyt PM. A review of solutions for diagnostic accuracy studies with an imperfect or missing reference standard. J Clin Epidemiol 2009;62:797-806. http://dx.doi.org/10.1016/j.jclinepi.2009.02.005
93. Trikalinos TA, Balion CM. Chapter 9: options for summarizing medical test performance in the absence of a ‘gold standard’. J Gen Intern Med 2012;27(1):67-75. http://dx.doi.org/10.1007/s11606-012-2031-7
94. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007;11(50). http://dx.doi.org/10.3310/hta11500
95. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. http://dx.doi.org/10.1016/0197-2456(86)90046-2
96. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-62. http://dx.doi.org/10.1136/bmj.323.7305.157
97. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9. http://dx.doi.org/10.1186/1471-2288-2-9
98. Irwig L, Macaskill P, Glasziou P, Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 1995;48:119-30. http://dx.doi.org/10.1016/0895-4356(94)00099-C
99. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31. http://dx.doi.org/10.1186/1471-2288-6-31
100. Harbord RM, Whiting P. metandi: Meta-analysis of diagnostic accuracy using hierarchical logistic regression. Stata J 2009;9:211-29.
101. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev 2013;2:71. http://dx.doi.org/10.1186/2046-4053-2-71
102. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. Am J Respir Crit Care Med 2011;183:88-95. http://dx.doi.org/10.1164/rccm.201006-0974OC
103. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M, et al. The tuberculin skin test versus QuantiFERON TB Gold in predicting tuberculosis disease in an adolescent cohort study in South Africa. PLOS ONE 2011;6:e17984. [Erratum published in PLoS One 2011;6(6)]. http://dx.doi.org/10.1371/journal.pone.0017984
104. Noorbakhsh S, Mousavi J, Barati M, Shamshiri AR, Shekarabi M, Tabatabaei A, et al. Evaluation of an interferon-gamma release assay in young contacts of active tuberculosis cases. East Mediterr Health J 2011;17:714-18.
105. Adetifa IM, Ota MO, Jeffries DJ, Hammond A, Lugos MD, Donkor S, et al. Commercial interferon gamma release assays compared to the tuberculin skin test for diagnosis of latent Mycobacterium tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect Dis J 2010;29:439-43. http://dx.doi.org/10.1097/INF.0b013e3181cb45da
106. Cruz AT, Geltemeyer AM, Starke JR, Flores JA, Graviss EA, Smith KC. Comparing the tuberculin skin test and T-SPOT.TB blood test in children. Pediatrics 2011;127:e31-8. http://dx.doi.org/10.1542/peds.2010-1725
107. Kasambira TS, Shah M, Adrian PV, Holshouser M, Madhi SA, Chaisson RE, et al. QuantiFERON-TB Gold In-Tube for the detection of Mycobacterium tuberculosis infection in children with household tuberculosis contact. Int J Tuberc Lung Dis 2011;15:628-34. http://dx.doi.org/10.5588/ijtld.10.0555
108. Mahomed H, Hawkridge T, Verver S, Geiter L, Hatherill M, Abrahams DA, et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int J Tuberc Lung Dis 2011;15:331-6.
109. Pavic I, Topic RZ, Raos M, Aberle N, Dodig S. Interferon-release assay for the diagnosis of latent tuberculosis in children younger than 5 years of age. Pediatr Infect Dis J 2011;30:866-70. http://dx.doi.org/10.1097/INF.0b013e318220c52a
110. Rutherford ME, Hill PC, Maharani W, Apriani L, Sampurno H, van Crevel R, et al. Risk factors for Mycobacterium tuberculosis infection in Indonesian children living with a sputum smear-positive case. Int J Tuberc Lung Dis 2012;16:1594-9. http://dx.doi.org/10.5588/ijtld.12.0389
111. Rutherford ME, Nataprawira M, Yulita I, Apriani L, Maharani W, van Crevel R, et al. QuantiFERON-TB Gold In-Tube assay vs. tuberculin skin test in Indonesian children living with a tuberculosis case. Int J Tuberc Lung Dis 2012;16:496-502. http://dx.doi.org/10.5588/ijtld.11.0491
112. Talbot EA, Harland D, Wieland-Alter W, Burrer S, Adams LV. Specificity of the tuberculin skin test and the T-SPOT.TB assay among students in a low-tuberculosis incidence setting. J Am Coll Health 2012;60:94-6. http://dx.doi.org/10.1080/07448481.2011.580029
113. Tsolia MN, Mavrikou M, Critselis E, Papadopoulos NG, Makrinioti H, Spyridis NP, et al. Whole blood interferon-release assay is a useful tool for the diagnosis of tuberculosis infection particularly among Bacille Calmette-Guérin-vaccinated children. Pediatr Infect Dis J 2010;29:1137-40. http://dx.doi.org/10.1097/INF.0b013e3181ebfe8a
114. Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, et al. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infect Dis 2011;11:319. http://dx.doi.org/10.1186/1471-2334-11-319
115. Moon SM, Lee SO, Choi SH, Kim YS, Woo JH, Yoon DH, et al. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis 2013;15:104-9. http://dx.doi.org/ 10.1111/j.1399-3062.2012.00765.x
116. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant 2011;11:1927-35. [Erratum published in Am J Transplant 2011;11:2541] http://dx.doi.org/10.1111/j.1600-6143.2011.03625.x
117. Anibarro L, Trigo M, Feijoo D, Rios M, Palomares L, Pena A, et al. Value of the tuberculin skin testing and of an interferon-gamma release assay in haemodialysis patients after exposure to M. tuberculosis. BMC Infect Dis 2012;12:195. http://dx.doi.org/10.1186/1471-2334-12-195
118. Lee SSJ, Chou KJ, Su IJ, Chen YS, Fang HC, Huang TS, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: comparison of quantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection 2009;37:96-102. http://dx.doi.org/10.1007/s15010-008-8082-3
119. Chang B, Park HY, Jeon K, Ahn JK, Cha HS, Koh EM, et al. Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. Clin Rheumatol 2011;30:1535-41. http://dx.doi.org/10.1007/s10067-011-1771-9
120. Ahmadinejad Z, Azmoudeh Ardalan F, Razzaqi M, Davoudi S, Jafarian A. QuantiFERON-TB Gold In-Tube test for diagnosis of latent tuberculosis (TB) infection in solid organ transplant candidates: a single-center study in an area endemic for TB. Transpl Infect Dis 2013;15:90-5. http://dx.doi.org/10.1111/tid.12027
121. Al Jahdali H, Ahmed AE, Balkhy HH, Baharoon S, Al Hejaili FF, Hajeer A, et al. Comparison of the tuberculin skin test and Quanti-FERON-TB Gold In-Tube (QFT-G) test for the diagnosis of latent tuberculosis infection in dialysis patients. J Infect Public Health 2013;6:166-72. http://dx.doi.org/10.1016/j.jiph.2013.02.002
122. Ates G, Ozekinci T, Yildiz T, Danis R. Comparison of interferon-gamma release assay versus tuberculin skin test for latent tuberculosis screening in hemodialysis patients. Biotechnol Biotechnol Equip 2009;23:1242-6. http://dx.doi.org/10.1080/13102818.2009.10817646
123. Casas S, Andreu A, Juanola X, Bordas X, Alcaide F, Moure R, et al. Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-release assay in patients considered for anti-tumor necrosis factor-alpha therapy. Diagn Microbiol Infect Dis 2011;71:57-65. http://dx.doi.org/10.1016/j.diagmicrobio.2010.12.020
124. Casas S, Muñoz L, Moure R, Castellote J, Guerra MR, Gonzalez L, et al. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation. Liver Transpl 2011;17:1205-11. http://dx.doi.org/10.1002/lt.22375
125. Chkhartishvili N, Kempker RR, Dvali N, Abashidze L, Sharavdze L, Gabunia P, et al. Poor agreement between interferon-gamma release assays and the tuberculin skin test among HIV-infected individuals in the country of Georgia. BMC Infect Dis 2013;13:513. http://dx.doi.org/10.1186/1471-2334-13-513
126. Chung WK, Zheng ZL, Sung JY, Kim S, Lee HH, Choi SJ, et al. Validity of interferon-release assays for the diagnosis of latent tuberculosis in haemodialysis patients. Clin Microbiol Infect 2010;16:960-5. http://dx.doi.org/10.1111/j.1469-0691.2009.02949.x
127. Costantino F, de Carvalho Bittencourt M, Rat AC, Loeuille D, Dintinger H, Bene MC, et al. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-release assay results. J Rheumatol 2013;40:1986-93. http://dx.doi.org/10.3899/jrheum.130303
128. Hadaya K, Bridevaux PO, Roux-Lombard P, Delort A, Saudan P, Martin PY, et al. Contribution of interferon-release assays (IGRAs) to the diagnosis of latent tuberculosis infection after renal transplantation. Transplantation 2013;95:1485-90. http://dx.doi.org/10.1097/TP.0b013e3182907073
129. Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al. Interferon-release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64:2068-77. http://dx.doi.org/10.1002/art.34382
130. Kim SH, Lee SO, Park IA, Park SJ, Choi SH, Kim YS, et al. Diagnostic usefulness of a T cell-based assay for latent tuberculosis infection in kidney transplant candidates before transplantation. Transpl Infect Dis 2010;12:113-19. http://dx.doi.org/10.1111/j.1399-3062.2010.00495.x
131. Kim SY, Jung GS, Kim SK, Chang J, Kim MS, Kim YS, et al. Comparison of the tuberculin skin test and interferon-release assay for the diagnosis of latent tuberculosis infection before kidney transplantation. Infection 2013;41:103-10. http://dx.doi.org/10.1007/s15010-012-0291-0
132. Kim JS, Cho JH, Park GY, Kang YJ, Kwon O, Choi JY, et al. Comparison of QuantiFERON-TB Gold with tuberculin skin test for detection of latent tuberculosis infection before kidney transplantation. Transplant Proc 2013;45:2899-902. http://dx.doi.org/10.1016/j.transproceed.2013.08.059
133. Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, et al. Screening for latent tuberculosis infection: performance of tuberculin skin test and interferon-release assays under real-life conditions. Ann Rheum Dis 2012;71:1791-5. http://dx.doi.org/10.1136/annrheumdis-2011-200941
134. Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009;161:797-800. http://dx.doi.org/10.1111/j.1365-2133.2009.09331.x
135. Maritsi D, Al-Obadi M, Brogan PA, Eleftheriou D, Dixon GL. The performance of Quantiferon TB Gold In-Tube as a screening tool in paediatric rheumatology prior to initiation of infliximab: a single centre’s experience. ISRN Rheumatol 2011;2011:505171. http://dx.doi.org/10.5402/2011/505171
136. Mutsvangwa J, Millington KA, Chaka K, Mavhudzi T, Cheung YB, Mason PR, et al. Identifying recent Mycobacterium tuberculosis transmission in the setting of high HIV and TB burden. Thorax 2010;65:315-20. http://dx.doi.org/10.1136/thx.2009.124891
137. Papay P, Eser A, Winkler S, Frantal S, Primas C, Miehsler W, et al. Factors impacting the results of interferon-release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:84-90. http://dx.doi.org/10.1002/ibd.21427
138. Ramos JM, Masia M, Rodriguez JC, Lopez C, Padilla S, Robledano C, et al. Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases. Clin Exp Med 2013;13:177-86. http://dx.doi.org/10.1007/s10238-012-0192-7
139. Seyhan EC, Sokucu S, Altin S, Gunluoglu G, Trablus S, Yilmaz D, et al. Comparison of the QuantiFERON-TB Gold In-Tube test with the tuberculin skin test for detecting latent tuberculosis infection in hemodialysis patients. Transpl Infect Dis 2010;12:98-105. http://dx.doi.org/10.1111/j.1399-3062.2009.00469.x
140. Shen KS, Zhang KY, Wang F, Yu L, Zhang SQ, Zhao WJ, et al. Diagnostic value of an IFN-gamma ELISPOT assay to detect latent tuberculosis infection in hepatitis C patients. Afr J Microbiol Res 2012;6:1736-41.
141. Takeda N, Nojima T, Terao C, Yukawa N, Kawabata D, Ohmura K, et al. Interferon-gamma release assay for diagnosing Mycobacterium tuberculosis infections in patients with systemic lupus erythematosus. Lupus 2011;20:792-800. http://dx.doi.org/10.1177/0961203310397966
142. Vassilopoulos D, Tsikrika S, Hatzara C, Podia V, Kandili A, Stamoulis N, et al. Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy. Clin Vaccine Immunol 2011;18:2102-8. http://dx.doi.org/10.1128/CVI.05299-11
143. Harstad I, Winje BA, Heldal E, Oftung F, Jacobsen GW. Predictive values of QuantiFERON-TB Gold testing in screening for tuberculosis disease in asylum seekers. Int J Tuberc Lung Dis 2010;14:1209-11.
144. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM, et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J 2010;35:1346-53. http://dx.doi.org/10.1183/09031936.00098509
145. Lucas M, Nicol P, McKinnon E, Whidborne R, Lucas A, Thambiran A, et al. A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 2010;65:442-8. http://dx.doi.org/10.1136/thx.2009.127555
146. Orlando G, Merli S, Cordier L, Mazza F, Casazza G, Villa AM, et al. Interferon-gamma releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants. Infection 2010;38:195-204. http://dx.doi.org/10.1007/s15010-010-0015-2
147. Saracino A, Scotto G, Fornabaio C, Martinelli D, Faleo G, Cibelli D, et al. QuantiFERON-TB Gold In-Tube test (QFT-GIT) for the screening of latent tuberculosis in recent immigrants to Italy. New Microbiol 2009;32:369-76.
148. Laniado-Laborin R, Cazares-Adame R, Volker-Soberanes ML, Del Portillo-Mustieles C, Villa-Rosas C, Oceguera-Palao L, et al. Latent tuberculous infection prevalence among paediatric contacts of drug-resistant and drug-susceptible cases. Int J Tuberc Lung Dis 2014;18:515-19. http://dx.doi.org/10.5588/ijtld.13.0840
149. Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, Kim DY, et al. A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. J Infect 2014;69:165-73. http://dx.doi.org/10.1016/j.jinf.2014.02.019
150. Metin Timur O, Tanir G, Oz FN, Bayhan GI, Aydin Teke T, Tuygun N. Comparison of QuantiFERON-TB Gold In-Tube test with tuberculin skin test in children who had no contact with active tuberculosis case. Tuberk Toraks 2014;62:116-21. http://dx.doi.org/10.5578/tt.3552
151. Perez-Porcuna TM, Ascaso C, Malheiro A, Abellana R, Martins M, Sardinha JFJ, et al. Mycobacterium tuberculosis infection in young children: analyzing the performance of the diagnostic tests. PLOS ONE 2014;9:e97992. http://dx.doi.org/10.1371/journal.pone.0097992
152. Song SE, Yang J, Lee KS, Kim H, Kim YM, Kim S, et al. Comparison of the tuberculin skin test and interferon gamma release assay for the screening of tuberculosis in adolescents in close contact with tuberculosis TB patients. PLOS ONE 2014;9:e100267. http://dx.doi.org/10.1371/journal.pone.0100267
153. Souza JMO, Evangelista MDSN, Trajman A. Added value of quantiFERON TB-Gold In-Tube for detecting latent tuberculosis infection among persons living with HIV/AIDS. Biomed Res Int 2014;2014:294963. http://dx.doi.org/10.1155/2014/294963
154. Tieu HV, Suntarattiwong P, Puthanakit T, Chotpitayasunondh T, Chokephaibulkit K, Sirivichayakul S, et al. Comparing interferon-gamma release assays to tuberculin skin test in Thai children with tuberculosis exposure. PLOS ONE 2014;9:e105003. http://dx.doi.org/10.1371/journal.pone.0105003
155. Sherkat R, Yaran M, Shoaie P, Mortazavi M, Shahidi S, Hamidi H, et al. Concordance of the tuberculin skin test and T-SPOT®.TB test results in kidney transplant candidates. J Res Med Sci 2014;19(1):26-9.
156. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9. http://dx.doi.org/10.1164/rccm.200402-232OC
157. Chun JK, Kim CK, Kim HS, Jung GY, Lee TJ, Kim KH, et al. The role of a whole blood interferongamma assay for the detection of latent tuberculosis infection in bacille Calmette-Guérin vaccinated children. Diagn Microbiol Infect Dis 2008;62:389-94. http://dx.doi.org/10.1016/j.diagmicrobio.2008.08.022
158. Connell TG, Curtis N, Ranganathan SC, Buttery JP. Performance of a whole blood interferon gamma assay for detecting latent infection with Mycobacterium tuberculosis in children. Thorax 2006;61:616-20. http://dx.doi.org/10.1136/thx.2005.048033
159. Connell TG, Ritz N, Paxton GA, Buttery JP, Curtis N, Ranganathan SC. A three-way comparison of tuberculin skin testing, QuantiFERON-TB gold and T-SPOT.TB in children. PLOS ONE 2008;3:e2624. http://dx.doi.org/10.1371/journal.pone.0002624
160. Hansted E, Andriuskeviciene A, Sakalauskas R, Kevalas R, Sitkauskiene B. T-cell-based diagnosis of tuberculosis infection in children in Lithuania: a country of high incidence despite a high coverage with bacille Calmette-Guérin vaccination. BMC Pulm Med 2009;9:41. http://dx.doi.org/10.1186/1471-2466-9-41
161. Higuchi K, Kondo S, Wada M, Hayashi S, Ootsuka G, Sakamoto N, et al. Contact investigation in a primary school using a whole blood interferon-gamma assay. J Infect 2009;58:352-7. http://dx.doi.org/10.1016/j.jinf.2009.02.019
162. Higuchi K, Harada N, Mori T, Sekiya Y. Use of QuantiFERON-TB Gold to investigate tuberculosis contacts in a high school. Respirology 2007;12:88-92. http://dx.doi.org/10.1111/j.1440-1843.2006.01000.x
163. Lighter J, Rigaud M, Eduardo R, Peng CH, Pollack H. Latent tuberculosis diagnosis in children by using the QuantiFERON-TB Gold In-Tube test. Pediatrics 2009;123:30-7. http://dx.doi.org/10.1542/peds.2007-3618
164. Okada K, Mao TE, Mori T, Miura T, Sugiyama T, Yoshiyama T, et al. Performance of an interferongamma release assay for diagnosing latent tuberculosis infection in children. Epidemiol Infect 2008;136:1179-87. http://dx.doi.org/10.1017/s0950268807009831
165. Tsiouris SJ, Coetzee D, Toro PL, Austin J, Stein Z, El-Sadr W. Sensitivity analysis and potential uses of a novel gamma interferon release assay for diagnosis of tuberculosis. J Clin Microbiol 2006;44:2844-50. http://dx.doi.org/10.1128/JCM.02411-05
166. Winje BA, Oftung F, Korsvold GE, Mannsaker T, Jeppesen AS, Harstad I, et al. Screening for tuberculosis infection among newly arrived asylum seekers: comparison of QuantiFERONTB Gold with tuberculin skin test. BMC Infect Dis 2008;8:65. http://dx.doi.org/10.1186/1471-2334-8-65
167. Balcells ME, Perez CM, Chanqueo L, Lasso M, Villanueva M, Espinoza M, et al. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. Int J Infect Dis 2008;12:645-52. http://dx.doi.org/10.1016/j.ijid.2008.03.005
168. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-93. http://dx.doi.org/10.1183/09031936.00107608
169. Cobanoglu N, Ozcelik U, Kalyoncu U, Ozen S, Kiraz S, Gurcan N, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007;11:1177-82.
170. Jones S, de Gijsel D, Wallach FR, Gurtman AC, Shi Q, Sacks H. Utility of QuantiFERON-TB Gold In-Tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis 2007;11:1190-5.
171. Luetkemeyer AF, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007;175:737-42. http://dx.doi.org/10.1164/rccm.200608-1088OC
172. Mandalakas AM, Hesseling AC, Chegou NN, Kirchner HL, Zhu X, Marais BJ, et al. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008;12:417-23.
173. Manuel O, Humar A, Preiksaitis J, Doucette K, Shokoples S, Peleg AY, et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007;7:2797-801. http://dx.doi.org/10.1111/j.1600-6143.2007.02011.x
174. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigenspecific interferon gamma assay. Ann Rheum Dis 2008;67:84-90. http://dx.doi.org/10.1136/ard.2007.070789
175. Piana F, Codecasa LR, Cavallerio P, Ferrarese M, Migliori GB, Barbarano L, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006;28:31-4. http://dx.doi.org/10.1183/09031936.06.00110205
176. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81.
177. Richeldi L, Losi M, D’Amico R, Luppi M, Ferrari A, Mussini C, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009;136:198-204. http://dx.doi.org/10.1378/chest.08-2575
178. Schoepfer AM, Flogerzi B, Fallegger S, Schaffer T, Mueller S, Nicod L, et al. Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease. Am J Gastroenterol 2008;103:2799-806. http://dx.doi.org/10.1111/j.1572-0241.2008.02050.x
179. Shovman O, Anouk M, Vinnitsky N, Arad U, Paran D, Litinsky I, et al. QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. Int J Tuberc Lung Dis 2009;13:1427-32.
180. Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009;36:1876-84. http://dx.doi.org/10.3899/jrheum.081292
181. Talati NJ, Seybold U, Humphrey B, Aina A, Tapia J, Weinfurter P, et al. Poor concordance between interferon-gamma release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009;9:15. http://dx.doi.org/10.1186/1471-2334-9-15
182. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (ELISPOT) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-6.
183. Brodie D, Lederer DJ, Gallardo JS, Trivedi SH, Burzynski JN, Schluger NW. Use of an interferongamma release assay to diagnose latent tuberculosis infection in foreign-born patients. Chest 2008;133:869-74. http://dx.doi.org/10.1378/chest.07-1815
184. Carvalho AC, Pezzoli MC, El-Hamad I, Arce P, Bigoni S, Scarcella C, et al. QuantiFERON-TB Gold test in the identification of latent tuberculosis infection in immigrants. J Infect 2007;55:164-8. http://dx.doi.org/10.1016/j.jinf.2007.02.004
185. Diel R, Nienhaus A, Lange C, Meywald-Walter K, Forssbohm M, Schaberg T. Tuberculosis contact investigation with a new, specific blood test in a low-incidence population containing a high proportion of BCG-vaccinated persons. Respir Res 2006;7:77. http://dx.doi.org/10.1186/1465-9921-7-77
186. Diel R, Loddenkemper R, Meywald-Walter K, Niemann S, Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-70. http://dx.doi.org/10.1164/rccm.200711-1613OC
187. Franken WP, Timmermans JF, Prins C, Slootman EJ, Dreverman J, Bruins H, et al. Comparison of Mantoux and QuantiFERON TB Gold tests for diagnosis of latent tuberculosis infection in army personnel. Clin Vaccine Immunol 2007;14:477-80. http://dx.doi.org/10.1128/CVI.00463-06
188. Janssens JP, Roux-Lombard P, Perneger T, Metzger M, Vivien R, Rochat T. Contribution of a IFN-gamma assay in contact tracing for tuberculosis in a low-incidence, high immigration area. Swiss Med Wkly 2008;138:585-93. http://dx.doi.org/2008/39/smw-12243
189. Kik SV, Franken WP, Arend SM, Mensen M, Cobelens FG, Kamphorst M, et al. Interferon-gamma release assays in immigrant contacts and effect of remote exposure to Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:820-8.
190. Nienhaus A, Schablon A, Bacle CL, Siano B, Diel R. Evaluation of the interferon-gamma release assay in healthcare workers. Int Arch Occup Environ Health 2008;81:295-300. http://dx.doi.org/10.1007/s00420-007-0212-1
191. Porsa E, Cheng L, Seale MM, Delclos GL, Ma X, Reich R, et al. Comparison of a new ESAT-6/ CFP-10 peptide-based gamma interferon assay and a tuberculin skin test for tuberculosis screening in a moderate-risk population. Clin Vaccine Immunol 2006;13:53-8. http://dx.doi.org/10.1128/CVI.13.1.53-58.2006
192. Winje BA, Oftung F, Korsvold GE, Mannsaker T, Ly IN, Harstad I, et al. School based screening for tuberculosis infection in Norway: comparison of positive tuberculin skin test with interferongamma release assay. BMC Infect Dis 2008;8:140. http://dx.doi.org/10.1186/1471-2334-8-140
193. Saiman L, Colson P. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics 2004;114:1175-201.
194. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ 2013;14:367-72. http://dx.doi.org/10.1007/s10198-013-0471-6
195. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8(36). http://dx.doi.org/10.3310/hta8360
196. Kowada A. Cost effectiveness of interferon-gamma release assay for tuberculosis screening of rheumatoid arthritis patients prior to initiation of tumor necrosis factor-alpha antagonist therapy. Mol Diagn Ther 2010;14:367-73. http://dx.doi.org/10.1007/BF03256394
197. Kowada A. Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening. Mol Diagn Ther 2012;16:181-90. http://dx.doi.org/10.1007/BF03262207
198. Kowada A. Cost effectiveness of the interferon-release assay for tuberculosis screening of hemodialysis patients. Nephrol Dial Transplant 2013;28:682-8. http://dx.doi.org/10.1093/ndt/gfs479
199. Kowada A. Cost effectiveness of interferon-release assay for TB screening of HIV positive pregnant women in low TB incidence countries. J Infect 2014;68:32-42. http://dx.doi.org/10.1016/j.jinf.2013.08.009
200. Laskin BL, Goebel J, Starke JR, Schauer DP, Eckman MH. Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. Am J Kidney Dis 2013;61:22-32. http://dx.doi.org/10.1053/j.ajkd.2012.06.004
201. Linas BP, Wong AY, Freedberg KA, Horsburgh CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011;184:590-601. http://dx.doi.org/10.1164/rccm.201101-0181OC
202. Swaminath A, Bhadelia N, Wang YC. Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. Inflamm Bowel Dis 2013;19:2444-9. http://dx.doi.org/10.1097/MIB.0b013e31829f008f
203. Mandalakas AM, Hesseling AC, Gie RP, Schaaf HS, Marais BJ, Sinanovic E. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 2013;68:247-55. http://dx.doi.org/10.1136/thoraxjnl-2011-200933
204. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999;3(2).
205. Hunink M, Glasziou P. Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge: Cambridge University Press; 2001.
206. The Human Mortality Database. URL: www.mortality.org/ (accessed 6 February 2015).
207. Health and Social Care Information Centre. Health Survey for England - 2012. Health and Social Care Information Centre; 2013. URL: www.hscic.gov.uk/catalogue/PUB13218 (accessed 2 November 2014).
208. Kumar N, Bhargava SK, Agrawal CS, George K, Karki P, Baral D. Chest radiographs and their reliability in the diagnosis of tuberculosis. JNMA J Nepal Med Assoc 2005;44:138-42.
209. Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, et al. Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis. BMC Pulm Med 2010;10:7. http://dx.doi.org/10.1186/1471-2466-10-7
210. White P, Jit M. What is the Cost-Effectiveness of Latent Tuberculosis Infection (LTBI) Treatment with Different Regimens? London: Imperial College Consultants; 2015.
211. Okuonghae D. A mathematical model of tuberculosis transmission with heterogeneity in disease susceptibility and progression under a treatment regimen for infectious cases. Appl Math Model 2013;37:6786-808. http://dx.doi.org/10.1016/j.apm.2013.01.039
212. Oxlade O, Schwartzman K, Benedetti A, Pai M, Heymann J, Menzies D. Developing a tuberculosis transmission model that accounts for changes in population health. Med Decis Making 2011;31:53-68. http://dx.doi.org/10.1177/0272989X10369001
213. Crofts JP, Pebody R, Grant A, Watson JM, Abubakar I. Estimating tuberculosis case mortality in England and Wales, 2001-2002. Int J Tuberc Lung Dis 2008;12:308-13.
214. Department of Health. NHS Reference Costs 2012 to 2013. London: Department of Health; 2013. URL: www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013 (accessed 21 November 2014).
215. Bothamley GH, Rowan JP, Griffiths CJ, Beeks M, McDonald M, Beasley E, et al. Screening for tuberculosis: the port of arrival scheme compared with screening in general practice and the homeless. Thorax 2002;57:45-9. http://dx.doi.org/10.1136/thorax.57.1.45
216. NHS Business Services Authority. NHS Electronic Drug Tariff: February 2015. NHS Business Services Authority; 2015. URL: www.ppa.org.uk/edt/February_2015/mindex.htm (accessed 19 February 2015).
217. Curtis L. Unit Costs of Health and Social Care 2013. Canterbury: Personal Social Services Research Unit, University of Kent; 2013. URL: www.pssru.ac.uk/project-pages/unit-costs/2013/ (accessed 1 December 2014).
218. Office for National Statistics. Population and Migration Data Catalogue. 2014. URL: www.ons.gov.uk/ons/guide-method/compendiums/compendium-of-uk-statistics/population-and-migration/data-catalogue/index.html (accessed 5 February 2014).
219. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84. http://dx.doi.org/10.7326/0003-4819-149-3-200808050-00241
220. Dheda K, Van Zyl Smit R, Badri M, Pai M. T-cell interferon-release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin Pulm Med 2009;15:188-200. http://dx.doi.org/10.1097/MCP.0b013e32832a0adc
221. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D. Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 2011;15:1018-32. http://dx.doi.org/10.5588/ijtld.10.0631
222. Santin M, Munoz L, Rigau D. Interferon-release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLOS ONE 2012;7:e32482. http://dx.doi.org/10.1371/journal.pone.0032482
223. Sarrazin H, Wilkinson KA, Andersson J, Rangaka MX, Radler L, van Veen K, et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J Infect Dis 2009;199:702-10. http://dx.doi.org/10.1086/596735
224. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 2012;142:63-75. http://dx.doi.org/10.1378/chest.11-3157
225. Song GG, Bae SC, Lee YH. Interferon-gamma release assays versus tuberculin skin testing in patients with rheumatoid arthritis. Int J Rheum Dis 2013;16:279-83. http://dx.doi.org/10.1111/1756-185X.12098
226. Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis 2012;18:2034-42. http://dx.doi.org/10.1002/ibd.22901
227. Schmidt RL, Factor RE. Understanding sources of bias in diagnostic accuracy studies. Arch Pathol Lab Med 2013;137:558-65. http://dx.doi.org/10.5858/arpa.2012-0198-RA
228. Public Health England. World Health Organization (WHO) Estimates of Tuberculosis Incidence by Rate, 2012 (Sorted by Rate). 2014. URL: www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/1195733837507 (accessed 1 July 2014).
229. Heldal E, Kuyvenhoven JV, Wares F, Migliori GB, Ditiu L, Fernandez Hoz K, et al. Diagnosis and treatment of tuberculosis in undocumented migrants in low or intermediate incidence countries. Int J Tuberc Lung Dis 2008;12:878-88.
230. Mor Z, Migliori GB, Althomsons SP, Loddenkemper R, Trnka L, Iademarco MF. Comparison of tuberculosis surveillance systems in low incidence industrialised countries. Eur Respir J 2008;32:1616-24.
231. Joint Formulary Committee. British National Formulary. 66 ed. London: BMJ Group and Pharmaceutical Press; 2013.